NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 4.2016 Featured Updates to the NCCN Guidelines

被引：332

作者：

Ettinger, David S. ^{[1
]}

Wood, Douglas E. ^{[2
]}

Akerley, Wallace ^{[3
]}

Bazhenova, Lyudmila A. ^{[4
]}

Borghaei, Hossein ^{[5
]}

Camidge, David Ross ^{[6
]}

Cheney, Richard T. ^{[7
]}

Chirieac, Lucian R. ^{[8
]}

D'Amico, Thomas A. ^{[9
]}

Dilling, Thomas J. ^{[10
]}

Dobelbower, M. Chris ^{[11
]}

Govindan, Ramaswamy ^{[12
,13
]}

Hennon, Mark ^{[7
]}

Horn, Leora ^{[14
]}

Jahan, Thierry M. ^{[15
]}

Komaki, Ritsuko ^{[16
]}

Lackner, Rudy P. ^{[17
]}

Lanuti, Michael ^{[18
]}

Lilenbaum, Rogerio ^{[19
]}

Lin, Jules ^{[20
]}

Loo, Billy W., Jr. ^{[21
]}

Martins, Renato ^{[2
]}

Otterson, Gregory A. ^{[22
,23
]}

Patel, Jyoti D. ^{[24
]}

Pisters, Katherine M. ^{[16
]}

Reckamp, Karen ^{[25
]}

Riely, Gregory J. ^{[26
]}

Schild, Steven E. ^{[27
]}

Shapiro, Theresa A. ^{[1
]}

Sharma, Neelesh ^{[28
,29
]}

Stevenson, James ^{[28
,29
]}

Swanson, Scott J. ^{[8
]}

Tauer, Kurt ^{[30
]}

Yang, Stephen C. ^{[1
]}

Gregory, Kristina ^{[31
]}

Hughes, Miranda ^{[31
]}

机构：

[1] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA

[2] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA

[3] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA

[4] UC San Diego Moores Canc Ctr, San Diego, CA USA

[5] Fox Chase Canc Ctr, Philadelphia, PA USA

[6] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA

[7] Roswell Pk Canc Inst, Buffalo, NY USA

[8] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA

[9] Duke Canc Inst, Durham, NC USA

[10] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[11] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL USA

[12] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA

[13] Washington Univ, Sch Med, St Louis, MO 63130 USA

[14] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[15] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[16] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[17] Fred & Pamela Buffett Canc Ctr, Durham, NC USA

[18] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[19] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA

[20] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[21] Stanford Canc Inst, Palo Alto, CA USA

[22] Ohio State Univ, James Canc Hosp, Ctr Comprehens Canc, Columbus, OH 43210 USA

[23] Solove Res Inst, Columbus, OH USA

[24] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA

[25] City Hope Comprehens Canc Ctr, Duarte, CA USA

[26] Mem Sloan Kettering Canc Ctr, New York, NY USA

[27] Mayo Clin, Ctr Canc, Rochester, MN USA

[28] Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA

[29] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA

[30] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA

[31] Natl Comprehens Canc Network, Ft Washington, PA USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2016年 / 14卷 / 03期

关键词：

NIVOLUMAB; IMMUNOTHERAPY; DOCETAXEL; SAFETY;

D O I：

10.6004/jnccn.2016.0031

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.

引用

页码：255 / 264

页数：10

共 23 条

[1] Advances in immunotherapy for treatment of lung cancer [J].

Alvarez, Jean G. Bustannante ;

Gonzalez-Cao, Maria ;

Karachaliou, Niki ;

Santarpia, Mariacarmela ;

Viteri, Santiago ;

Teixido, Cristina ;

Rosell, Rafael .

CANCER BIOLOGY & MEDICINE, 2015, 12 (03) :209-222

[2]

BESSE B, PHASE 2 TRIAL BIRCH

[3] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[4] Nivolumab: targeting PD-1 to bolster antitumor immunity [J].

Brahmer, Julie R. ;

Hammers, Hans ;

Lipson, Evan J. .

FUTURE ONCOLOGY, 2015, 11 (09) :1307-1326

[5] Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population [J].

Brzezianska, Ewa ;

Karbownik, Malgorzata ;

Migdalska-Sek, Monika ;

Pastuszak-Lewandoska, Dorota ;

Wloch, Jan ;

Lewinski, Andrzej .

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2006, 599 (1-2) :26-35

[6] Rapid Eradication of a Bulky Melanoma Mass with One Dose of Immunotherapy [J].

Chapman, Paul B. ;

D'Angelo, Sandra P. ;

Wolchok, Jedd D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (21) :2073-2074

[7] Pseudoprogression and Immune-Related Response in Solid Tumors [J].

Chiou, Victoria L. ;

Burotto, Mauricio .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (31) :3541-+

[8]

Ettinger D S, 1996, Oncology (Williston Park), V10, P81

[9] Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer [J].

Garon, Edward B. ;

Rizvi, Naiyer A. ;

Hui, Rina ;

Leighl, Natasha ;

Balmanoukian, Ani S. ;

Eder, Joseph Paul ;

Patnaik, Amita ;

Aggarwal, Charu ;

Gubens, Matthew ;

Horn, Leora ;

Carcereny, Enric ;

Ahn, Myung-Ju ;

Felip, Enriqueta ;

Lee, Jong-Seok ;

Hellmann, Matthew D. ;

Hamid, Omid ;

Goldman, Jonathan W. ;

Soria, Jean-Charles ;

Dolled-Filhart, Marisa ;

Rutledge, Ruth Z. ;

Zhang, Jin ;

Lunceford, Jared K. ;

Rangwala, Reshma ;

Lubiniecki, Gregory M. ;

Roach, Charlotte ;

Emancipator, Kenneth ;

Gandhi, Leena .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (21) :2018-2028

[10] Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer [J].

Gettinger, Scott N. ;

Horn, Leora ;

Gandhi, Leena ;

Spigel, David R. ;

Antonia, Scott J. ;

Rizvi, Naiyer A. ;

Powderly, John D. ;

Heist, Rebecca S. ;

Carvajal, Richard D. ;

Jackman, David M. ;

Sequist, Lecia V. ;

Smith, David C. ;

Leming, Philip ;

Carbone, David P. ;

Pinder-Schenck, Mary C. ;

Topalian, Suzanne L. ;

Hodi, F. Stephen ;

Sosman, Jeffrey A. ;

Sznol, Mario ;

McDermott, David F. ;

Pardoll, Drew M. ;

Sankar, Vindira ;

Ahlers, Christoph M. ;

Salvati, Mark ;

Wigginton, Jon M. ;

Hellmann, Matthew D. ;

Kollia, Georgia D. ;

Gupta, Ashok K. ;

Brahmer, Julie R. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18) :2004-U32

← 1 2 3 →